Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (DE:SRT3)
:SRT3
Holding DE:SRT3?
Track your performance easily
SRT3 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€199.50 - €383.70
Previous CloseN/A
Volume14.14K
Average Volume (3M)91.07K
Market Cap
€14.61B
Enterprise Value€22.47B
Total Cash (Recent Filing)$72.07M
Total Debt (Recent Filing)$451.95M
Price to Earnings (P/E)193.2
Beta1.63
Next Earnings
Jan 28, 2025EPS Estimate
1.07Last Dividend Ex-Date
Apr 02, 2024Dividend Yield0.32%
Share Statistics
EPS (TTM)1.21
Shares Outstanding37,440,000
10 Day Avg. Volume107,163
30 Day Avg. Volume91,070
Standard Deviation0.12
R-Squared0.03
Alpha0.00947
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue5.38
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda14.94
Forecast
1Y Price Target
€256.60Price Target Upside10.60% Upside
Rating ConsensusHold
Number of Analyst Covering10
Sartorius AG News
PremiumPre-Earnings
Is 0NIR a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Bioprocessing GrowthSequential order intake growth of ~8% in Bioprocessing is seen as a key positive.
Financial PerformanceA solid finish to the year is expected with likely positive risk/reward given trends into 4Q, cost cuts, and the more conservative guide towards the midpoint at the 3Q.
Orderbook OutlookOrderbooks are improving, indicating a better outlook for Sartorius AG.
Bears Say
Financial PerformanceEBITDA decreased disproportionately from lower economies of scale.
Market ConditionsLPS continues to show weak end markets with reluctance for investment from customers, particularly in China.
Revenue ChallengesBioprocessing recovery is still slow, indicating challenges in achieving revenue targets.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
14.73% Mutual Funds
<0.01% Other Institutional Investors
77.82% Public Companies and
Individual Investors
SRT3 FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €199.50 and its highest was €383.70 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €14.61B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jan 28, 2025 which is in 6 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Oct 17, 2024. The company reported €0.21 earnings per share for the quarter, missing the consensus estimate of €0.859 by -€0.649.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.74 which represents an annual dividend yield of 0.32%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.07.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €0.21 in its last earnings report, missing expectations of €0.859. Following the earnings report the stock price went up 16.448%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in DE:SRT3
---
Sartorius AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€256.60 (10.60% Upside)
€256.60 (10.60% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.44%
12-Months-Change
Fundamentals
Return on Equity
3.51%
Trailing 12-Months
Asset Growth
-1.67%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. In 2019, the bioprocess division contributed 77% to total revenue and the lab division the remaining 23%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (38% of 2019 sales), the Americas (37%), and Asia-Pacific (25%). Sartorius employs over 9,000 people and has operations in more than 30 countries.
---
SRT3 Stock 12 Month Forecast
Average Price Target
€256.60
▲(10.60% Upside)
Technical Analysis
Best Analysts Covering SRT3
1 Year
1 Year Success Rate
15/38 ratings generated profit
1 Year Average Return
+4.72%
reiterated a buy rating 16 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 39.47% of your transactions generating a profit, with an average return of +4.72% per trade.
---